Combretastatin anticancer drugs

Drugs of the Future

Volumn 27, Issue 5, 2002, Pages 475-480

  Bibby, Michael C ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COMBRETASTATIN; COMBRETASTATIN A1; COMBRETASTATIN A4; COMBRETASTATIN DERIVATIVE; DOXORUBICIN; FLUOROURACIL; N ACETYLCOLCHINOL PHOSPHATE; PACLITAXEL; PRODRUG; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; UNCLASSIFIED DRUG; VINFLUNINE;

ANTINEOPLASTIC ACTIVITY; CANCER; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0036324971     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.05.668645     Document Type: Review

References (53)

1. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients - A phase II study
2. Phase II trial of weekly iv vinorelbine as a single agent in first line advanced breast cancer chemotherapy - The Latin-American experience
3. Vinca alkaloids in superacid media: A method for creating a new family of antitumor derivatives
4. Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentration
5. Promotion of microtubule assembly in vitro by Taxol
6. Isolation, structure and synthesis of combretastatins A1 and B1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum
7. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A4
8. Interactions of combretastatin, a new plant derived antimitotic agent with tubulin
9. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile
10. Role of B-ring of colchicine in its binding to tubulin
11. The interaction with tubulin of a series of stilbenes based on combretastatin A-4
12. Antineoplastic agents 322. Synthesis of combretastatin A4 prodrugs
13. Anti-vascular approaches to solid tumor therapy: Evaluation of tubulin binding agents
14. The effect of colchicine on normal and neoplastic tissue in mice
15. Combretastatin A4, an agent that displays potent and selective toxicity towards tumour vasculature
16. Combination chemotherapy with combretastatin A4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma
17. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
18. Targeting the tumor vasculature with combretastatin A4 disodium phosphate: Effects on radiation therapy
19. Combretastatin A-4 disodium phosphate: A vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy
20. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-0-phosphate
21. In vivo and in vitro evaluation of combretastatin A4 and its sodium phosphate prodrug
22. Non invasive in vivo assessment of tumor perfusion after antiangiogenic therapy with combretastatin A4 with dynamic contrast-enhanced MR1
23. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4
24. Combretastatin A4 phosphate as a tumor vascular-targeting agent: Early effects in normal tissues
25. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
26. Differences in chemosensitivity between subcutaneous and pulmonary tumours
27. Modulation of the tumor-cell response to chemotherapy by the organ environment
28. Characterization of the vasculature within a murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies
29. Potent antimetastatic activity of combretastatin-A4
30. Combretastatin A4 pro-drug study of the effect on the growth and the microvasculature of colorectal liver metastases in a murine model
31. Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines
32. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: Preclinical efficacy
33. Phase I/pharmacokinetic trial of the endothelial toxin combretastatin A4P (CA4P) administered as an IV bolus on a daily x 5 schedule every 21 days
34. Phase I pharmacokinetic and toxicity study of weekly intravenous combretastatin A4 phosphate (CA4P)
35. Combretastatin A4 phosphate targets vasculature in animal and human tumours
36. A phase I pharmacokinetic (PK) study of single dose intravenous (IV) combretastatin A4 phosphate (CA4P) in patients with advanced cancer: Final report
37. Novel combretastatin analogues effective against murine solid tumors: Design and structure-activity relationships
38. Syntheses and antitumor activity of cis-restricted combretastatins: 5-Membered heterocyclic analogues
39. Novel B-ring modified combretastatin analogues: Syntheses and antineoplastic activity
40. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy
41. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative AC7700
42. Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect
43. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors
44. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs
45. Podophyllotoxin, steganacin and combretastatin: Natural products that bind at the colchicine binding site of tubulin
46. Combretastatin A-1 phosphate a novel tubulin binding agent with in vivo antivascular effects in experimental tumors
47. Vinca alkaloids: Anti-vascular effects in a murine tumour
48. Anti-vascular effects of vinflunine in the MAC15A transplantable adenocarcinoma model
49. Potent, orally active heterocycle-based analogs: Synthesis, structure-activity relationship, pharmacokinetics and in vivo antitumor activity evaluation
50. Anti-tumour activity of the novel vascular targeting agent ZD6126 in a human lung tumour xenograft model
51. ZD6126, a novel vascular targeting agent induces rapid changes to tumor blood vessel endothelial cells in an Hras5 nude mouse xenograft
52. A phase I dose-escalation trial of ZD6126, a novel vascular targeting agent, in patients with cancer refractory to other treatments